• 10.11.19

    Retail and Consumer Products Law Roundup October 2019

    In a closely watched case that many hoped would bring some clarity—and sanity—to the subject of website accessibility under the Americans with Disabilities Act, the Supreme Court has instead chosen to punt.

  • 07.22.19

    Update on Drug Pricing Transparency: What’s Next?

    On July 9, Judge Amit P. Mehta of the U.S. District Court, District of Columbia vacated an administration final rule that would have required drug manufacturers to disclose wholesale acquisition prices in their television broadcast advertising.

  • 06.25.19

    The Final Rule’s Impact on Drug Pricing Transparency

    In May 2018, the President and the Department of Health & Human Services (HHS) rolled out the Drug Pricing Blueprint, outlining the administration’s agenda for dealing with high drug prices.

  • 06.25.19

    Significant Changes Proposed to Medicare Part D Benefit

    On May 23, the bipartisan leadership of the House Ways and Means Committee released a four-page draft discussion bill that, if enacted, would make the most significant changes to the Part D benefit since the Affordable Care Act’s changes to the coverage gap.

  • 05.22.19

    Available Now—Drug Pricing Transparency Rule: What You Need to Know

    On May 8, the administration issued the much-anticipated final rule requiring drug manufacturers to disclose wholesale acquisition prices in their broadcast advertising.

  • 02.14.19

    HHS Proposes Revising Anti-Kickback Safe Harbor on Pharmaceutical Rebates

    On January 31, the Department of Health & Human Services (HHS) Office of Inspector General (OIG) issued a proposed rule to fundamentally change the system for negotiating drug prices under Medicare Part D and, potentially, for other government and private payers.

  • 12.19.18

    Proposed Changes Increase Drug Competition in Medicare Part D

    On November 26 2018, the Centers for Medicare & Medicaid Services (CMS) released the Proposed Rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses,which can be found here.

  • 11.26.18

    New Podcast: Would CMS’s Drug Price Transparency Requirement Really Lower Prices?

    On October 15, the Trump administration published a proposed rule that, if finalized, would require prescription drugmakers to include drug price information in broadcast advertising.

  • 08.21.18

    President Trump’s Drug Pricing Plan: What’s Next?

    The Administration’s drug pricing plan, “American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs,” unveiled in May included tough rhetoric for the stakeholders in the pharmaceutical industry, including manufacturers, payers, ...

  • 03.20.18

    The Promise of Data-Driven Healthcare: Megatrends for 2018

    There is a quote by science fiction writer Amelia Atwater-Rhodes that is the ideal lead-in to any discussion about healthcare data and analytics: “Life is nothing without a little chaos to make it interesting.”